Copyright
©2008 The WJG Press and Baishideng.
World J Gastroenterol. Oct 7, 2008; 14(37): 5695-5700
Published online Oct 7, 2008. doi: 10.3748/wjg.14.5695
Published online Oct 7, 2008. doi: 10.3748/wjg.14.5695
Table 5 Clinical features of DM2 in HCC patients of the FU and CO groups (%)
FU group | CO group | P | |
Prevalence of DM2 | 92 (30.2) | 53 (33.1) | 0.51 |
HbA1c (mean% ± SD) | 8.2 ± 2.78 | 7.1 ± 2.12 | 0.1 |
Insulin therapy | 45 (48.9) | 15 (28.3) | 0.01 |
Antidiabetic oral agents | 47 (51.1) | 38 (71.7) | 0.01 |
Diet with/without metformin | 7 (14.9) | 4 (10.5) | 0.55 |
Sulfonylureas with/without metformin | 40 (85.1) | 34 (89.5) | 0.55 |
Duration of DM2 (mean ± SD, mo) | 127.8 ± 80.1 | 167.1 ± 114.3 | 0.03 |
Duration of insulin therapy (mean ± SD, mo) | 50.0 ± 50.5 | 77.8 ± 86.4 | 0.12 |
- Citation: Donadon V, Balbi M, Casarin P, Vario A, Alberti A. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: Potential role of insulin. World J Gastroenterol 2008; 14(37): 5695-5700
- URL: https://www.wjgnet.com/1007-9327/full/v14/i37/5695.htm
- DOI: https://dx.doi.org/10.3748/wjg.14.5695